FDA gives orphan drug designation to BIV201 for ascites treatment

The Food and Drug Administration has given an orphan drug designation to the compound BIV201 for the treatment of ascites, according to a press release from the drug’s manufacturer, BioVie. The FDA...
Source: Hospitalist News - Category: Hospital Management Source Type: research